Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.43 |
| ▸ | STK4 | Q13043 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110576 | 0.98 | DHFR (0.48) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 | |
| SCHEMBL4118866 | 0.90 | DHFR (0.50) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 | |
| SCHEMBL4115440 | 0.88 | DHFR (0.46) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 | |
| SCHEMBL4100252 | 0.88 | IRAK4 (0.49) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 | |
| SCHEMBL4101836 | 0.88 | FGFR1 (0.52) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 | |
| SCHEMBL4078984 | 0.88 | ADORA1 (0.47) | ADORA1IRAK4IRAK1FGFR1KDR | |
| SCHEMBL4120078 | 0.88 | QPCT (0.42) | DHFRIRAK4IRAK1SYKFGFR1 | |
| SCHEMBL3978332 | 0.87 | SMN1; SMN2 (0.59) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 | |
| SCHEMBL4082424 | 0.87 | IRAK4 (0.48) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 | |
| SCHEMBL4109415 | 0.86 | DHFR (0.45) | DHFRADORA1ADORA2ASMN1; SMN2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | claimed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | DHFR 1013/4885ADORA1 303/4885ADORA2A 341/4885 |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | PRKCA, PRKCG, PRKCH | DHFR 1013/4885ADORA1 303/4885ADORA2A 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.